Resarch programme: anti-cancer therapeutics - Oncology Research International

Drug Profile

Resarch programme: anti-cancer therapeutics - Oncology Research International

Alternative Names: ORI007; ORIL 007; ORIL 019; ORIL 025

Latest Information Update: 31 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oncology Research International
  • Developer Oncology Research International; University of Adelaide; Womens and Childrens Hospital
  • Class
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Colorectal cancer

Most Recent Events

  • 31 Jan 2017 Preclinical trials in Cancer in Australia (Topical)
  • 31 Jan 2017 Preclinical trials in Cancer in Australia (unspecified route)
  • 20 Jul 2016 Preclinical trials in Colorectal cancer in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top